News on 12-8 at 4:30 PM "Exicure announced results from its completed Phase 2 trial evaluating burixafor in combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation."
Broker:Interactive Brokers
| Date | Price | |
|---|---|---|
| Entry | 12/9/2025 | 9.25 |
| Exit | 12/9/2025 | 9.178 |
- Total Views6
- Position Size1
- Percentage-0.78%
Proof
Copy and paste the following into your page or blog. If using WordPress, you must paste this in the HTML tab only:
